11^th European Biosimilars Congress

David Ebsworth has over 35 years of experience in the Global Pharmaceutical industry, largely with Bayer AG covering senior management roles in Leverkusen, Germany, the US and Canada. Aside from Bayer, where he worked for over 19 years, he spent two years as Chairman of A&D Pharma-Holdings NV in Bucharest, Romania. He also served as Chief Executive Officer of Oxford Glycosciences (OGS), a biotech company listed on the LSE and NASDAQ stock exchanges, which was acquired by Celltech plc (now part of UCB) in 2003. OGS was the world leader in proteomics and had development compounds for Gaucher's disease and cancer. He has served on a number of Boards within the pharma, biotech and venture capital sectors, in the UK, Germany, the US, Austria, Italy, Israel, Netherlands, and Japan. During the past five years, he has held directorships at Xention Ltd, Wilex AG and Intercell AG. He was CEO and Chairman of Executive Committee; responsible for the Galenica Group, coordination of Sante Business and CEO of Vifor Pharma for almost three years until August 2014, after which he remained for an year as Executive Vice President, supporting two new CEOs.